Laura Calabresi

Florence, 50139, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

CD20+ T Cells in Multiple Sclerosis: From Pathogenesis to Treatment-Induced Depletion.

CD20+ T Cells in Multiple Sclerosis: From Pathogenesis to Treatment-Induced Depletion.

Journal: International journal of molecular sciences

Published: June 18, 2025

Ropeginterferon phase 2 randomized study in low-risk polycythemia vera: 5-year drug survival and efficacy outcomes.

Ropeginterferon phase 2 randomized study in low-risk polycythemia vera: 5-year drug survival and efficacy outcomes.

Journal: Annals of hematology

Published: November 13, 2023

Clonal dynamics and copy number variants by single-cell analysis in leukemic evolution of myeloproliferative neoplasms.

Clonal dynamics and copy number variants by single-cell analysis in leukemic evolution of myeloproliferative neoplasms.

Journal: American journal of hematology

Published: June 13, 2023

Inhibition of ERK1/2 signaling prevents bone marrow fibrosis by reducing osteopontin plasma levels in a myelofibrosis mouse model.

Inhibition of ERK1/2 signaling prevents bone marrow fibrosis by reducing osteopontin plasma levels in a myelofibrosis mouse model.

Journal: Leukemia

Published: November 23, 2022

Immunoblotting-assisted assessment of JAK/STAT and PI3K/Akt/mTOR signaling in myeloproliferative neoplasms CD34+ stem cells.

Immunoblotting-assisted assessment of JAK/STAT and PI3K/Akt/mTOR signaling in myeloproliferative neoplasms CD34+ stem cells.

Journal: Methods in cell biology

Published: August 11, 2022

The MPL mutation.

The MPL mutation.

Journal: International review of cell and molecular biology

Published: November 10, 2021

Activated IL-6 signaling contributes to the pathogenesis of, and is a novel therapeutic target for, CALR-mutated MPNs.

Activated IL-6 signaling contributes to the pathogenesis of, and is a novel therapeutic target for, CALR-mutated MPNs.

Journal: Blood advances

Published: August 28, 2020

Enhanced engraftment of human myelofibrosis stem and progenitor cells in MISTRG mice.

Enhanced engraftment of human myelofibrosis stem and progenitor cells in MISTRG mice.

Journal: Blood advances

Published: December 17, 2019

Extramedullary blastic transformation of primary myelofibrosis in the form of disseminated myeloid sarcoma: a case report and review of the literature.

Extramedullary blastic transformation of primary myelofibrosis in the form of disseminated myeloid sarcoma: a case report and review of the literature.

Journal: Clinical and experimental medicine

Published: November 05, 2019

Calreticulin Ins5 and Del52 mutations impair unfolded protein and oxidative stress responses in K562 cells expressing CALR mutants.

Calreticulin Ins5 and Del52 mutations impair unfolded protein and oxidative stress responses in K562 cells expressing CALR mutants.

Journal: Scientific reports

Published: July 31, 2018

CALR mutational status identifies different disease subtypes of essential thrombocythemia showing distinct expression profiles.

CALR mutational status identifies different disease subtypes of essential thrombocythemia showing distinct expression profiles.

Journal: Blood cancer journal

Published: August 28, 2017

Inhibitors of the PI3K/mTOR pathway prevent STAT5 phosphorylation in JAK2V617F mutated cells through PP2A/CIP2A axis.

Inhibitors of the PI3K/mTOR pathway prevent STAT5 phosphorylation in JAK2V617F mutated cells through PP2A/CIP2A axis.

Journal: Oncotarget

Published: February 28, 2017

Showing 1-12 of 14

Last Updated: 09/26/2026